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Abstract: 
The reverse transcriptase (RT) enzyme is the prime target of nucleoside/ nucleotide (NRTI) and non-nucleoside (NNRTI) reverse transcriptase 
inhibitors.  Here we investigate the structural basis of effects of drug-resistance mutations in clade C RT using three-dimensional structural 
modeling. Apropos the expectation was for unique mechanisms in clade C based on interactions with amino acids of p66 subunit in RT molecule.  
3-D structures of RT with mutations found in sequences from 2 treatment naïve, 8 failed and one reference clade C have been modeled and 
analyzed. Models were generated by computational mutation of available crystal structures of drug bound homologous RT. Energy minimization 
of the models and the structural analyses were carried out using standard methods. Mutations at positions 75,101,118,190,230,238 and 318 
known to confer drug resistance were investigated.  Different mutations produced different effects such as alteration of geometry of the drug-
binding pocket, structural changes at the site of entry of the drug (into the active site), repositioning the template bases or by discriminating the 
inhibitors from their natural substrates.  For the mutations analyzed, NRTI resistance was mediated mainly by the ability to discriminate between 
inhibitors and natural substrate, whereas, NNRTI resistance affected either the drug entry or the geometry of the active site.  Our analysis 
suggests that different mutations result in different structural effects affecting the ability of a given drug to bind to the RT. Our studies will help 
in the development of newer drugs taking into account the presence of these mutations and the structural basis of drug resistance.    
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Background: 
Human immunodeficiency virus type -1 (HIV-1) belongs to the family 
Retroviridae.  Like all the other members of this family it requires the 
enzyme reverse transcriptase (RT) to reverse transcribe the genomic 
RNA into DNA.  The HIV-1 RT is the prime target of nucleoside 
reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse 
transcriptase inhibitors (NNRTIs) which are used in antiretroviral 
therapy (ART). In India, a combination from NRTIs and NNRTIs are 
used as first line drugs to treat HIV-1 infections.    
 
The RT enzyme has two polymerase activities, namely, RNA-
dependent DNA polymerization and DNA-dependent DNA 
polymerization  [1].  The RT is a heterodimer consisting of two 
subunits p66 and p51 [1, 2]. The p66 subunit consists of 560 amino 
acids whereas the p51 subunit consists of 440 amino acids. The 
additional 120 amino acids in p66 are responsible for the ribonuclease 
H (RNase H) activity [2].  The p66 subunit is responsible for the 
enzymatic activity of the RT and contains the DNA binding groove 
and the active site.  The p66 has an ‘open’ conformation to enable it to 
‘grasp’ the template. The overall shape of the p66 subunit has been 
compared to that of a right hand [2].  It is composed of the “fingers” 
(residues 1-85, 118-155), “palm” (86-117, 156-237) and “thumb” 
(238-318).  The “palm” subdomain is the location of the catalytic 
aspartate residues (D110, D185, D186) [2].  In addition, it also has the 
‘connection’ (319-426) and the RNase H. The p51 subunit functions 
more as a scaffold for p66 and has a closed conformation. It has no 
enzymatic activity [1-3].  
 
The RT of HIV-1 can develop mutations that can hamper interactions 
to NRTIs and NNRTIs which translates to resistance to RT inhibitors.  
The mechanisms of resistance of many of these mutations have been 
studied and crystal structures of these mutant RTs are available in 
protein data bank (PDB). In this study, we report our studies to 
elucidate structural basis of plausible mechanisms of resistance 
conferred by certain mutations in clade C HIV-1 strains observed in 
Indian patients. We have generated three-dimensional structural 
models to postulate mechanisms of resistance induced by these 
mutations.   
 
Methodology: 
Blood samples were collected from HIV-1 infected treatment naïve 
individuals and treatment experienced patients who were failing ART. 
They had come to the Clinical Virology department of a tertiary care 
hospital in south India for CD4+ T- cell estimation and/or HIV-1 viral 
load during the years 2005-2007. The pol gene of these strains was 
amplified by an in-house PCR, this sequence data was used only for 
the development of the models [4, 5].  This derived work was part of 
another study wherein we looked at HIV-1 drug resistance.  It 
involved amplification of the HIV-1 protease and RT gene to obtain an 
1800 bp amplicon.  
 
RT sequences from 10 strains (8 from treatment failure and 2 from 
treatment naïve groups) (Table 1 in supplementary material) and 
one reference clade C (AAY23520.1) was selected to generate three 
dimensional models. The treatment naïve group was selected based on 
the presence of unusual mutation/mutations not seen in clade B strains 
based on results obtained from the Stanford HIV-1 drug resistance 
database. The 3D modeling was done for these variants, some known 
to confer drug resistance in Clade B and some are newly found in 
clade C. The data on mutational patterns were based on information Bioinformation    open access 
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got from the Stanford HIV drug resistance database. The nucleotide 
sequences were translated using the ExPasy translate tool 
(http://www.expasy.ch/tools/dna.html). The translated sequences were 
aligned using clustalw (http://www.ebi.ac.uk/clustalw/). 
 
Three dimensional models were generated by mutating the available 
crystal structures of drug bound and unbound RT using the 
Biopolymer tool of Sybyl (Tripos Inc., St. Louis, MO). The protein 
databank codes of the crystal structures of bound and unbound forms 
of RT used in this study are 1IKW
 [6], 1VRT
 [7], 1DLO [8], 1HMV 
[9], 1RTJ [10] and 1RTD [11]. Energy minimizations were carried out 
by targeting the sites of mutations and neighborhood using the 
Maximin tool of Sybyl package.   All the atoms that were within a 
distance of 6Å (Angstrom) from the mutated residue (“HOT” region), 
were allowed to move during minimization.  Kollman United force 
field  [12] available in Sybyl package was used for energy 
minimization. A cutoff of 9Å was used for calculating non-bonded 
interactions. The inhibitor molecule was not included during energy 
minimization since the sites of most of the mutations are not located 
on the active site. We have used caricature modeling to postulate 
changes in the RT that could affect drug affinity.  Mustang [13] and 
DALI  [14, 15] were used for multiple and pair-wise structure 
superposition respectively. PyMOL (DeLano Scientific LLC, San 
Carlos, California) and Setor [16] were used to visualize modeled 
protein structures and to analyze interactions between amino acid 
residues. 
 
 
Figure 1: (A) Location of Lys 101 in the unliganded RT structure, 1RTJ. p66 subunit is coloured in yellow while the p55 subunit is in pink 
(Same subunit colouring code is followed for the other figures). The part of the NNRTI entry site in the p66 subunit and the side chain of Lys 101 
are coloured green. The part of drug entry site in the p55 subunit is coloured in orange. (B-F) Local hydrogen bond interactions involving K101 
in unliganded RT structure 1DLO,1HMV,1RTD, 1RTJ and in Nevirapine bound RT 1VRT (G) Structural superposition of 1IKW (yellow) and 
1RTJ (green) showing changes in residue conformations. (H) Interaction pattern involving K101 in Efavirenz (shown in orange) bound RT 
(1IKW) (I) Changes due to K101H mutation. Site of mutation (here and in the rest of the figures) is shown in pink. All the figures are rendered in 
PyMol. Bioinformation    open access 
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Figure 2: (A) Location of M230 (green) in Efavirenz (in orange) bound RT (1IKW) Interactions involving M230 in unliganded RT structures (B) 
1DLO and (C) 1RTJ. (D) RT structure that corresponds to open conformation (1RTJ, green) superposed on Efavirenz (in orange) bound RT 
(1IKW, yellow) (E) Interactions involving M230 in Nevirapine bound RT (1VRT) (F) Model for M230L mutation. 
 
Discussion: 
In this study we have studied eight mutations found in the Clade-C 
strains that confer resistance to both the classes of reverse transcriptase 
inhibitors viz., NRTIs and NNRTIs.  Mutations that confer resistance 
to these two groups of drugs are distinct.  We have mainly studies 
hydrogen bond interactions and van der Waals contacts involving the 
site of mutation. The changes in the local interaction patterns were 
then interpreted with the help of models for these mutations. The local 
interaction patterns found in the drug bound RT and absent in the 
unliganded protein, is expected to have some significance in 
stabilizing the drug bound form here we try to identify such 
interactions involving the site of mutation. 
Mutations like K101H, M230L and K238T confer resistance to 
NNRTIs by affecting drug entry into the binding pocket and by 
altering the geometry of the pocket. Other mutations like G190A and 
Y318F directly affect drug binding. 
 
Mutations such as V75M, V118I and Q151M that confer resistance to 
NRTIs act by affecting certain interactions that help dNTP (deoxy 
Nucleotide Tri Phosphate) or the drug binding. This not only involves 
interactions between the drug and RT but also interactions between the 
drug and the template RNA. 
 
K101H 
Figure 1A shows the location of Lys 101 in the wild type unliganded 
RT crystal structure (1RTJ). In the ligand unbound RT structure, the 
side chain of Tyr 181 points into the hydrophobic pocket where the 
NNRTIs bind (Figure 1B-E) This conformation is stabilized by the 
hydrogen bonds formed by the side chain hydroxyl group of Tyr 181 
with the side chain N-H group of Asn 136 of the p55 subunit (1DLO, 
IRTD) and with side chain carboxyl of Glu 138 of the p55 subunit 
(1HMV) (Figure 1B-D). The side chain of Lys 101 interacts with Pro 
321 through van der Waals forces. In some structures (1DLO, 1RTD), 
it also interacts with the side chain carboxyl of Glu 28 through a weak 
salt bridge (Figure 1B, D, E). In the template/primer bound RT 
structure (1RTD), Lys 101 side chain makes van der Waals contacts 
with the side chain of Tyr 319 (Figure 1D). In the structure of RT 
(1RTJ), which largely corresponds to open conformation (Figure S1 
in supplementary material), Lys 101 forms a salt bridge with Glu 28. 
It interacts with Glu 138 through water mediated hydrogen bonds 
(Figure 1E).  
 
In efavirenz and nevirapine bound RT structures (1IKW, 1VRT), Lys 
101 forms salt bridge with Glu 138. The side chain carboxyl of Glu 
138 also interacts with Gln136 through a NH---O hydrogen bond 
(Figure 1F, H) Efavirenz directly interacts with the main chain 
carbonyl and amino groups of Lys 101 through hydrogen bonds. 
Nevirapine forms water mediated hydrogen bonds with the main chain 
amino group and carboxyl groups of Lys 101 (Figure 1F, H). The 
conformational changes that occur in NNRTI binding pocket upon 
ligand binding are shown in Figure 1G.  As a result of the mutation 
Lys 101 → His (K101H), the salt bridge that Lys 101 forms with Glu 
138 is lost (Figure 1I) due to the shorter sidechain of Histidine. This 
might alter the geometry of the binding pocket. The loss of this salt Bioinformation    open access 
www.bioinformation.net    Hypothesis
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bridge might also affect the hydrogen bond interaction between Glu 
138 and Gln 136 and their side chains are likely to become more 
flexible. This increases the possibilities of interaction between Glu 
138/Gln 136 and Tyr 181, thereby affecting the inhibitor entry into the 
pocket. The direct or water mediated interactions with Efavirenz and 
Nevirapine also get affected because of changes in the side chain 
conformation. 
 
 
Figure 3: (A) Interactions involving Tyr 318 in Efavirenz (orange) bound RT (1IKW) and (B) Changes due to Y318F mutation. (C) Local 
interaction network involving Lys238 in Efavirenz bound RT structure (1IKW). (D)Changes due to K238T mutation (E) Comparison of side 
chain conformations of residues in the region involving Lys238, of Efavirenz bound RT, 1IKW (yellow) and of the unliganded form, 1RTJ 
(green) (F) Interactions involving K238 in Nevirapine bound RT (1VRT). Bioinformation    open access 
www.bioinformation.net    Hypothesis
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Figure 4 (A) Location of V75 with respect to dNTP (orange) binding site. Some residues in the vicinity of V75 involved in dNTP binding are 
also shown. (B) Interaction between Val 75, Phe 77 and neighbors (C) Model forV75M mutation (D) Residues in the vicinity of V75 involved in 
template RNA binding. 
 
M230L 
The position of M230L mutation site in Efavirenz bound RT structure 
is shown in Figure 2A.   In the ligand unbound RT structures in the 
closed conformation (1DLO,1HMV), Met 230 interacts with the side 
chain of Pro 95 through van der Waals forces (Figure 2B). The side 
chain carboxyl of Asp 186 and the side chain amino group of Trp 266 
forms hydrogen bonds with the main chain amino and carbonyl group 
of Met 230, respectively. The sulphur atom of Met 230 interacts with 
the  π clouds of Tyr 183 and Trp 229 (<5Å distance). In ligand 
unbound RT structure close to open conformation (1RTJ), Met 230 
interacts with Trp 266 side chain through sulphur-π (pi) interaction 
(Figure 2C). 
 
In RT bound to Efavirenz and Nevirapine (1IKW, 1VRT), Met 230 
sulphur atom is located close to the side chain of Tyr 183 (Figure 2D, 
E). The side chain aromatic rings of Tyr 183 and Trp 229 interact 
through π-π stacking. NH of Trp 229 can also interact with the π cloud 
of Tyr 183 (Figure 2E). 
 
When NNRTI enters the hydrophobic pocket, the side chains of Tyr 
181 and Tyr 188 move upward, giving space for the incoming 
inhibitor. This movement is accompanied by changes in side chain 
conformations of Trp 229, Tyr 183 and Phe 227. The side chain 
conformations of Tyr 183 and Trp 229 are stabilized by their 
interactions among themselves as well as with Met 230. The 
conformational changes of the residues that occur in the NNRTI 
binding pocket are shown in Figure 2D. The mutation M230L results 
in the loss of these interactions, as leucine has a smaller size compared 
to methionine and can thus affect the entry of the inhibitor (Figure 
2F). The interaction with Trp 266 which is in a loop joining palm and 
thumb sub-domains might have a role in stabilizing the structure of RT 
at different conformations. Thus, this mutation could also alter the 
flexibility of RT.    
 
G190A 
Gly 190 in NNRTI bound RT structures makes van der Waals contacts 
with the drugs Neviarpine and Efavirenz.  When Ala replaces Gly as a 
result of the mutation, the ￿-carbon in the Ala side chain, is at a 
distance of 2.46 A and 2.58A from one of the fluorine atoms of 
Efavirenz and from the cyclo propyl group of nevirapine respectively. 
These are too short distances and would result in steric clash which 
can seriously affect the binding of the drug. 
 
Y318F 
The site of Y318F mutation in Efavirenz bound RT (1IKW) is shown 
in Figure 3.   The O-H group in the side chain of Tyr 318 in the 
NNRTI bound complex (1IKW) interacts with the main chain carbonyl 
of His 235 through O-H…O hydrogen bond. This interaction helps to 
hold the side chain of Tyr 318 away from the NNRTI binding site 
(Figure 3A).  
 
The mutation Y318F results in the loss of this interaction as Phe lacks 
a hydrogen bonding group in its sidechain. This will make Phe 318 
side chain more flexible, thereby affecting inhibitor binding. The side Bioinformation    open access 
www.bioinformation.net    Hypothesis
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chain hydroxyl of Tyr 318 is at a distance of 3.3Å from Efavirenz and 
there are favourable van der Waals contacts between them. These 
interactions are also lost as a result of this mutation (Figure 3B). 
 
K238T 
The interaction network involving Lys 238 shown in Figure 3C, might 
have a role in maintaining the geometry of the NNRTI binding pocket. 
The mutation K238T would disrupt this interaction network and cause 
changes in the binding pocket (Figure 3D). RT structure in the open 
conformation (1RTJ, green) superposed on Efavirenz bound RT 
(1IKW, yellow) is shown in Figure 3E.  In the NNRTI bound RT 
structures, Lys 238 interacts with His 235 through van der Waals 
contacts. Lys 238 side chain makes van der Waals contacts, also with 
His 315. The side chain amino group forms a salt bridge with the side 
chain carboxyl of Asp 237 (weak in the case of Nevirapine bound RT 
(1VRT, Figure 3F). The change in His 235 side chain conformation, 
as a result of the mutation, could also affect Tyr 318 - His 235 
interaction. 
 
V75M 
The location of Val 75 with respect to dNTP binding site is shown in 
Figure 4A.  In the RNA template/primer bound RT (1RTD), Val 75 
interacts with Phe 77, Val 60 and Lys 73 through van der Waals 
contacts. Phe 77 makes extensive van der Waals contacts with the 
neighboring residues (Figure 4B). These interactions help to hold the 
antiparellel beta sheet (β3- β4) and the loop involving residues 64-70 
over the bound dNTP.  van der Waals contacts between Phe 77 and 
Pro 150 help to position Gln 151 that interacts directly with the dNTP. 
 
The structural model for V75M mutation shows (Figure 4C) that 
terminal methyl group of Met 75 side chain is close to Phe 77. The 
side chain of Phe 77 also moves to avoid steric clashes and to facilitate 
formation of sulphur-π interaction between these two residues. This 
affects the structural environment of the neighborhood. The hydrogen 
bond interaction between Lys 73 and Tyr 146 that help to hold the β3- 
β4 loop in position might be affected.  The residues in the vicinity of 
Val 75 and Phe 77 such as Phe 61, Asp 76 and Arg 78 (Figure 4D) 
interact with the template strand. These interactions could also be 
affected as a result of the mutation and the position of template bases 
might be altered. 
 
V118I 
The position of Val 118 in template/primer bound RT structure is in a 
hydrophobic environment with tight packing.  In the template/primer 
and TTP bound RT (1RTD), Val 118 interacts with Leu 149 and Phe 
160 through van der Waals contacts (Figure S2A in supplementary 
material). In the V118I mutant model (Figure S2B in supplementary 
material), we note changes in the side chain conformation of Tyr 115, 
Leu 149 and Ser 156 owing to the bulkier -CH2-CH3 group in the 
sidechain of Ile compared to Val which has only –CH3. Tyr 115 
interacts directly with the dNTP. Ser 156 forms O-H---O hydrogen 
bond with the main chain carbonyl of Pro 150 and this interaction aid 
in positioning Gln 151 for dNTP binding. Thus the side chain 
conformational changes of these residues triggered by the presence of 
bulkier Ile in the place of Val 118 would affect dNTP binding. 
 
Q151M 
In the template/primer and TTP bound RT structure (Figure S2C in 
supplementary material), the side chain NH of Gln 151 interacts 
with the main chain carbonyl at Lys 43 through a N-H…O hydrogen 
bond. The side chain carbonyl of Gln 151 also forms hydrogen bonds 
with side chain N-H of Arg 72 and one of the phosphate oxygens of 
dTTP. These interaction help directly or indirectly in TTP binding. 
The side chain of Gln 151 also forms van der Waals contacts with TTP 
and the side chain benzene rings of Tyr 115 and Phe 116. 
 
The mutation Q151M (Figure S2D in supplementary material) 
would cause a loss of the hydrogen bond interactions due to apolar 
nature of Met sidechain. The dramatic loss of these interactions in the 
mutant could affect the closing of β3-β4 loop upon dNTP binding. 
Though the side chain sulphur of Met 151 can interact with the π cloud 
of Phe 116 the terminal carbon of Met 151 side chain is at a distance 
of 2.27Å from one of the phosphate oxygens of dTTP. This would lead 
to steric clashes and can hamper the binding of dNTP. 
 
The mutation Q151M shows high resistance to AZT, D4T, and DDI 
[3]. The difference between these drugs and others like DDC, 3TC etc 
is that they interact with the template base through 2 hydrogen bonds 
(A-T base pairing) and not three. Also, in case of dNTPs the hydrogen 
bond that the 3'OH forms is an additional interaction that can stabilize 
the bound dNTP. So the mutations that affect certain interactions that 
stabilize the dNTP bound to the N site can be thought to be tools for 
discriminative selection.   
 
Conclusion: 
The mutations were primarily seen to affect drug efficacy by a number 
of ways such as altering the geometry of the drug binding pocket, 
perturbing the entry of the drug into the active site, repositioning the 
template bases and by discriminating the inhibitors from their natural 
substrates.  These are similar to the mechanisms that are known for 
clade B strains [3, 17]. The mutations that were analyzed in this study 
conferred resistance to both NRTIs and NNRTIs (Figure S3 in 
supplementary material). Drugs belonging to these two classes have 
different mechanisms of actions and hence the sites of mutations on 
RT would also be expected to be distinct.  NRTI resistance analyzed in 
this study was mediated either by discrimination between inhibitors 
and natural substrate or by template repositioning, whereas, NNRTI 
resistance affected the geometry of the active site, drug binding and 
entry. Sites of residue polymorphisms (not seen in Clade B strains) 
found in most of our Clade C strains are shown in Figure S4 (see 
supplementary material). Similar to HIV-1 protease, RT is also a 
dynamic enzyme but unlike in the former the mutations do not greatly 
hamper the dynamics of the enzyme [18, 19].  Resistance in RT can 
broadly be seen as changes in interactions at the active site of the 
enzyme which can in turn affect its behavior to the inhibitors. Newer 
groups of drugs in this class would need to take into account these 
mutations to be effective. RT does present itself as a potent target [3].  
There are two copies of RT in a HIV virion and each catalyzes about 
20,000 nucleotide incorporations. Thus, there are approximately 5,000 
chances for chain termination. We have studied only at a part of the 
protein and this may not reflect the behavior of the entire enzyme. 
However, since the study looks at changes in interactions of the amino 
acids on or near the drug binding site, it is likely that our approach is 
useful but within its limits.   
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Supplementary material 
 
Table 1: List of Genbank IDs of the sequences and mutations observed in the strains that were used to generate the models in this study 
GenBank ID  Subtype (% 
similarity) 
NRTI resistance 
Mutations 
NNRTI  
resistance 
mutations 
Other mutations 
EU037772  C (92.9%)  D67N,K7R,  
V118I, M184V, 
T215F, K219E 
K101H, 
Y181C, 
G190A 
V35T, T39D, V60I, L120FL, D121Y, K122E, 
I135T, S162A, K166R, K173A, D177E, T200A, 
Q207E, R211K, L228H, V245Q, A272P, V292I, 
I293V 
EU037773 C  (93.0%)  M184V  Y188L, 
Y318F 
V35M, E36A, T39D, S48T, V90FILV, P95LPQR, 
D121Y, K122E, D123E, K126KN, K173A, 
D177E, T200A, Q207E, R211K, V245Q, A272P, 
K275I, K277R, K281R, T286A, T290APST, 
E291D, V292I, I293V, E297A, R307K, S322A 
EU037774   C(93.0%) M184V,  T215F  K103N, 
V108I, 
M230L 
V35T,E36A,T39E,S48T,V60I,D121Y, 
K122E,I135T,S162A,K166R,K173A,D177E,T200
A,E203D,Q207E,H221Y,V245Q,A272P,K277R,K
281R,E291D,V292I,I293V, E297A, H315R 
EU037775 C(93.0%)  D67N,  K70R, 
V118I, M184V, 
T215F, K219E 
K101H, 
Y181C, 
G190A 
V35T, T39D, N57KN, V60I, K73N, D121Y, 
K122E, I135T, S162A, K166R, K173A, D177E, 
T200A, Q207E, R211K, D218E, L228H, V245Q, 
A272P, V292I, I293V 
EU037776 C(94.8%)  M184V  Y188L  T12S,  K14R, I15V, L19T, E35D, M36I, R41K, 
L63P, H69K, L89M, I93L V35M, T39D, S48T, 
D121Y, K122E, D123E, K173A, D177E, T200A, 
Q207E, R211K, F214L, V245Q, A272P, K277R, 
T286A, E291D, V292I, I293V, E297A 
EU037777 C(92.4%)  M41L,  D67N, 
T69D, K70R, 
V75M, M184V, 
T215F, K219Q 
K103S, 
G190A 
I31L, V35T, T39N, S48T, V60I, D121Y, K122E, 
T139K, I142V, S162A, K173A, Q174K, D177E, 
Q197H, T200A, Q207E, H208Y, R211K, L228H, 
V245K, A272P, E291D, V292I, I293V 
EU037778 C(92.6%)  K65KMR,K70KM
R, V75I, F77L, 
Y115F, F116Y, 
Q151M, M184V 
Y188L V35T,  T39N,  S48T,  V60I, S68G, V106I, D121Y, 
K122E, I135V, S162A, K173A, D177E, I178V, 
G196E, T200A, Q207E, Y232H, V245E, A272P, 
K277R, T286A, E291D, V292I, I293V, 
EU037779 C(94.1%)    K103N, 
V108ILV, 
K238IKRT 
Q23LPQR, V35I, E36A, T39D, S48T, V60I, 
V90FILV, D121Y, K122E, K173T, Q174K, 
D177DE, T200A, Q207E, V245Q, A272P, V276I, 
K281R, T286A, E291D, V292I, I293V 
EU0110067 C(94.4%)    Y181C  V35T,  E36A, T39D, S48T, V60I, K104R, D121Y, 
K122E, S162A, K173T, D177E, T200A, Q207E, 
R211K, D237N, V245Q, D250E, A272P, E291D, 
V292I, I293D 
EU0110054 C(93.3%)    K103R  V35T,  T39I, S48T, V60I, T139A, E169D, K173A, 
D177E, T200A, Q207E, R211K, V245Q, A272P, 
K277R, K281R, T286A, E291D, V292I, I293V, 
E297A, 
 Bioinformation    open access 
www.bioinformation.net    Hypothesis
 
ISSN 0973-2063 (online) 0973-8894 (print)     
Bioinformation 4(1): 36-45 (2009)    © 2009 Biomedical Informatics 
 
44
 
Figure S1: Comparison of structures of HIV-1 RT (1DLO-yellow, 1RTJ-pink, 1RTD-green) showing conformational changes from a closed to a 
DNA bound form. 
 
 
Figure S2: (A) Contacts between Val 118 and the neighbors. dTTP bound at the N site is shown in orange. (B) Changes in the side chain 
conformations due to V118I mutation. (C) Interactions involving Q151 and neighbors in template/primer bound RT. (D) Model for Q151M 
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Figure S3: (A) Structure of NNRTI (Efavirenz , shown in blue) bound HIV-1 RT (1IKW) showing the site of inhibitor binding. 
(B)  Structure of NRTI (dTTP, shown in blue) bound HIV-1 RT (1RTD) showing the site of inhibitor binding. 
(C) Structure of Efavienz bound RT showing the sites of NNRTI resistant mutations (residues indicated in red) analysed in this study. 
(D) Template/primer and dTTP bound form of HIV RT showing the sites of NRTI resistant mutations (in red), discussed in this study 
 
 
Figure S4: Structure of Efavirenz (orange) bound RT, showing the sites of common residue polymorphisms in Clade C, highlighted in light blue 
color. The thumb, palm and finger domains are shown in green, red and blue respectively. 
 
 